Suven Pharma inks pact with CSIR-IICT for process technology transfer of Molnupiravir

Anthony Fernandes
/ Categories: Trending, DSIJ News
Suven Pharma inks pact with CSIR-IICT for process technology transfer of Molnupiravir

Suven Pharmaceuticals Limited (SPL) announced that it has entered into an agreement for the process technology transfer & manufacturing of the anti-COVID drug, Molnupiravir, and 2-DG with CSIR Indian Institute of Chemical Technology (CSIR-IICT) and CSIR National Institute of Interdisciplinary Science & Technology (CSIR-NIIST).   

Molnupiravir is an antiviral drug developed for the treatment of influenza and has been repurposed to completely suppress the COVID virus transmission within 24 hours, according to the study recently published in the journal, Nature Microbiology.  

The agreements involve a total fee of Rs 8 lakh plus taxes for the non-exclusive grant of the licences to SPL. The process and know-how of the drug were sourced from CSIR-NIIST while the scale-up process was successfully carried out by CSIR-IICT. The agreement will enable SPL to manufacture and launch in the domestic market as an effective medication for COVID-infected patients, subject to regulatory approvals.  

At 12.44 pm on Friday, the company’s stock was trading at Rs 490.70, up by 2.05 per cent on BSE.  

Rate this article:
4.7

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR